 BOCA RATON, Fla., Aug. 29, 2022 GLOBE NEWSWIRE -- First Wave BioPharma, Inc., NASDAQ:FWBI, First Wave BioPharma or the Company, a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal GI diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, will present at the 2022 H.C. Wainwright 24th Annual Global Investment Conference. The conference is taking place September 12-14, 2022, at the Lotte New York Palace Hotel, New York City. 